Enlivex Therapeutics LtdNASDAQ:ENLV
- LAST PRICE1.3600
- TODAY'S CHANGE (%)0.0101 (0.7482%)
- Bid / Lots1.1600/ 5
- Ask / Lots1.3900/ 2
- Open / Previous Close1.3500 / 1.3499
- Day Range
- 52 Week Range
- Volume7,239
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ENLV |
|---|---|---|
| 10:01 ET | 115 | 1.35 |
| 10:21 ET | 100 | 1.34 |
| 10:44 ET | 150 | 1.3082 |
| 11:47 ET | 100 | 1.315 |
| 12:39 ET | 3900 | 1.3299 |
| 01:01 ET | 100 | 1.34 |
| 01:03 ET | 1099 | 1.335 |
| 01:24 ET | 100 | 1.36 |
| 02:18 ET | 100 | 1.36 |
| 03:09 ET | 175 | 1.36 |
May 29, 2024
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering, from 4:15PM ET on Wednesday May 29, 2024 by Dow Jones
4:15PM ET on Wednesday May 29, 2024 by Dow Jones
May 28, 2024
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering, from 8:12AM ET on Tuesday May 28, 2024 by Dow Jones
8:12AM ET on Tuesday May 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Enlivex Therapeutics Ltd | 28.1M | -0.9x | --- |
Biomx Inc | 27.9M | -0.6x | --- |
NanoViricides Inc | 28.4M | -3.0x | --- |
RenovoRx Inc | 27.8M | -1.6x | --- |
BioVie Inc | 27.8M | -0.5x | --- |
Viracta Therapeutics Inc | 27.5M | -0.6x | --- |
Company Information
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Contact Information
- Headquarters
- 14 Einstein St.NESS-ZIONA, Israel 7403618
- Phone
- ---
- Fax
- ---
Executives
- Chief Executive Officer
- Oren Hershkovitz
- Executive Chairman of the Board
- Shai Novik
- Founder, Chief Scientific Officer and Medical Officer
- Dror Mevorach
- Chief Financial Officer
- Shachar Shlosberger
- Director
- Baruch Halpert
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $28.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 20.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $-1.56 |
Book Value | $1.62 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
